Arrowhead’s New Deal With Takeda Strengthens The Company’s Value Proposition (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (ARWR) is a long-term holding of mine that just recently announced a partnership deal with Takeda (NYSE:TAK) for its ARO-AAT developmental stage therapy. I love this deal and think it yet again shows how well management is strategically and efficiently advancing an impressive pipeline through clinical development.

Arrowhead’s Deal with Takeda is a Win-Win for the Company

On October 8, Arrowhead announced that it had struck a deal with Takeda to co-develop and co-commercialize ARO-AAT, the company’s developmental therapy to treat alpha-1 antitrypsin-associated liver disease (AATLD). The partners will split US profits 50/50, and Takeda received an exclusive license to the therapy in the rest of the world for which Arrowhead will receive 20-25% royalties on net sales.

In exchange for this deal, Takeda is paying Arrowhead $300 million upfront and up to $740 million more in various potential developmental, regulatory, and commercial milestone payments.

I described the

Read More

What is proposition 22? The ballot measure that could determine the future of Uber and Lyft in California

The ballot measure, known as Proposition 22, would establish drivers as an independent class of workers with access to limited job benefits, along with wage and worker protections they’ve so far lacked under the gig economy model. Labor groups and many of driver advocates say the companies’ efforts, however, do not go far enough to protect workers and are merely an attempt, cloaked in friendly marketing materials, to quash a new law that would guarantee drivers access to the minimum wage, employer-provided health care and bargaining rights.

Drawing on a more than $186 million campaign war chest that Uber, Lyft, food delivery app DoorDash and other tech companies have raised, they are seeking to convince California voters that the ballot initiative reflects the will of drivers. They’ve cited limited survey data saying the vast majority of drivers want to remain contractors.

But critics see the measure as a last-ditch effort

Read More

Brain Mapping Foundation tackles COVID-19 pandemic through science, technology, innovation, and policy endorsing California Proposition 14-2020

Proposition 14-2020 provides $5.5B in total to continue stem cell research including $1.5B for the support of research and development of treatments toward neurological disorders.

LOS ANGELES, Sept. 16, 2020 /PRNewswire/ — Brain Mapping Foundation (BMF) and Society for Brain Mapping and Therapeutics (SBMT) have been on the forefront of combatting COVID-19 with their enormous network of scientists, physicians, and engineers worldwide.  BMF and SBMT formed a COVID-19 global taskforce in February of 2020 and by the first week of March they were connected to 5 different global taskforces in Asia, South America, North America, Middle East and India in real time. “Our taskforce coordinated efforts with our global membership and collaborators to rapidly advance our understanding of COVID-19,” said Vicky Yamamoto, Ph.D., Executive Director of SBMT, Co-Chair of COVID-19 Taskforce and Cancer Scientist, USC-Keck School of Medicine, Department of Otolaryngology/Head and Neck Surgery

Read More